Reuters reports that insurers, drug companies and industry watchers all agree that neither HMOs nor the Medicare program have focused significant attention on the high costs of new biotechnology drugs for cancer, rheumatoid arthritis, multiple sclerosis and other diseases. While the biotech drugs currently serve a narrow population, more expensive biotech medicines are expected to come on the market as the U.S. population ages, creating greater pressure on prices. Said one biotech industry executive, "We have to measure these drugs' benefit to society against how we spend money on other things."

Full Story:

Related Summaries